Honasa Consumer Ltd Q1 FY27 Earnings Call: Derma Co Crosses Rs. 1,000 Cr ARR, Guides 150-200 Bps Margin Expansion

Honasa Consumer Ltd held its Q1 FY27 earnings call on August 13, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Start with 32% Revenue Growth and Record Profitability

• 32% revenue growth (YoY, Q1 FY 2026-2027) with 30.5% volume growth; PAT of Rs.90 crores and cash generation of Rs.83 crores
• EBITDA of Rs.110 crores (incl. ~Rs.10 crores one-time Opex benefit); normalized EBITDA margin of 12.5% (Q1 FY 2026-2027)
• Focus categories grew 35%+ and contributed 85% of revenue in Q1 FY 2026-2027
• EBITDA margin benefited from mix impact (300-350 bps), operating leverage (~100 bps), summer seasonality (~50 bps), and a non-recurring one-time Opex benefit
• Crude oil price inflation due to West Asia war impacted packaging costs; company deferred cost impact in Q1 FY 2026-2027, with real impact expected in Q2 FY 2026-2027 — calibrated price increases taken at end of Q1

Mamaearth Accelerates, Derma Co Crosses Rs.1,000 Crore ARR

• Mamaearth accelerated to high-teens growth (Q1 FY 2026-2027); Mamaearth's GT growth exceeded the company's average GT growth
• Derma Co became the second Rs.1,000 crore ARR brand and entered the "teens" EBITDA club
• BTM Ventures (acquired Jan 2026) reached Rs.150 crore ARR, growing nearly 100% since acquisition
• Younger brands (excl. BTM Ventures) grew at 30%+ in Q1 FY 2026-2027
• Management targets Rice franchise to become Rs.500 crore ARR and Rosemary shampoo to become Rs.250 crore ARR over the next three years (by ~FY 2029-2030), both at single-digit market shares
• Emerging product candidates: moisturizers near Rs.50 crore ARR; Vitamin D daily glow sunscreen as next Rs.100 crore candidate; tea tree face wash and laminilo shampoo targeted to become Rs.100 crore franchises over 2-3 years
• Aqualogica performed well after its restage and relaunch in Q1 FY 2026-2027, targeting Gen Z (now 45% of D2C buying cohort on e-commerce)

Fickin Fragrance Launch and Honasa Health Subsidiary Open New Frontiers

• Launched fragrance brand "Fickin" — India's first elixir-based perfume with clinically tested 12-hour long-stay and patented design; fragrance penetration in India is 3% vs 11% globally
• Honasa Health subsidiary created to pursue nutrition and wellness, described as a "decadal opportunity"; Fluence (Vons Pharma) acquisition remains in due diligence
• Management prioritises organic R&D in nutrition/wellness but remains open to inorganic opportunities that add brands and capabilities
• Learned from earlier Mamaearth fragrance foray that winning in fine fragrances requires fragrance-first branded products, not brand extensions — the line was discontinued due to lack of product-market fit
• Over the past two years (FY 2024-25 and FY 2025-26), Honasa built internal R&D capabilities for fragrance development, focusing on notes, layering, and longevity
• Management noted that pure-play BPC companies globally (e.g., L'Oréal, Estée Lauder) have strong fragrance businesses, making fragrance a relevant category for such companies

150-200 bps Margin Expansion Guided for FY 2026-2027 Amid Cost Headwinds

• Management guided for EBITDA margin improvement of 150-200 bps in FY 2026-2027 vs FY 2025-2026, with a "long-term target of 500 basis points improvement over five years"
• Management reaffirmed "five-year target to reach 15% EBITDA margin by expanding 100-150 bps each year" (by ~FY 2031-2032)
• Distribution inventory is now at less than 30 days; retail STRs are healthier than category averages, citing real-time distributor tracking and record-high collections
• Crude oil price inflation due to West Asia war impacted packaging costs; company managed inventory effectively in Q1 FY 2026-2027, deferring cost impact — real impact expected in Q2 FY 2026-2027
• Calibrated price increases taken at end of Q1 FY 2026-2027 to offset procurement inflation; management hopes for reversal in H2 FY 2026-2027
• Management will prioritise reinvestment in growth, potentially making near-term margin guidance conservative

Offline Momentum Continues with 40%+ GT and MT Growth

• General trade secondary growth of 40%+ and modern trade offtakes of 40%+ in Q1 FY 2026-2027; market share gains of 350 bps in face washes, 160 bps in shampoos
• AC Nielsen measured "retail outlet reach of 3 lakh" in Q1 FY 2026-2027, largely driven by Mamaearth; Dermaco has ~50,000 offline outlets (MT + GT)
• GT growth driven by existing geographies and focused distribution strategy narrowing direct coverage from 150 to 100 cities
• E-commerce grew 20%+ in Q1 FY 2026-2027; quick commerce and tier-2+ markets identified as key growth levers
• CEO stated branded searches account for 50-60% of e-commerce sales and an even higher proportion on QC, reinforcing QC as a "branded purchase play" that benefits strong brands
• CEO views QC as a "constrained physical space play" where velocity per square foot will determine long-term winners, favouring brands with high consumer pull
• Dermaco's channel mix: 80% online, 20% offline (GT+MT) as of Q1 FY 2026-2027

FY 2026-2027 Revenue Growth to Exceed High-Teens CAGR Target

• CEO guided that Honasa's overall revenue growth in FY 2026-2027 will exceed the earlier communicated five-year CAGR target of high teens, with the company prioritising reinvestment for faster growth
• Mamaearth brand growth in FY 2026-2027 expected to outperform the planned double-digit CAGR over the next five years, supported by distribution gains
• Q2 FY 2026-2027 typically sees lower sequential scale vs Q1 due to fading summer category seasonality
• Q2 FY 2026-2027 will have a clean base post-Flipkart settlement, making reported growth equal to like-for-like growth
• Management expects continued growth and profitability improvement in the core portfolio to fund investments in new categories and brands